Video

Dr. Sapisochin on Determining Transplant Eligibility in HCC

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.

Gonzalo Sapisochin, MD, assistant professor, Division of General Surgery, Department of Surgery, University of Toronto, discusses factors that help determine transplant eligibility in hepatocellular carcinoma (HCC).

In the United States, the Milan criteria inform which patients are eligible for liver transplantation, says Sapisochin. Patients are eligible for transplant if they have a single tumor diameter <5 cm, ≤3 foci of tumor, each one ≤3 cm, no angioinvasion, and no extrahepatic involvement.

Protocols including transarterial chemoembolization can help down-stage patients and allow those with slightly larger tumors to become transplant eligible, explains Sapisochin.

At the University of Toronto, factors beyond the size and extent of the tumor, which take into account the heterogeneity of the tumor, may influence a patient’s eligibility status, says Sapisochin. These include the tumor biology and alpha fetoprotein levels. Notably, there are not as many limitations to transplant for patients with living donors, concludes Sapisochin.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center